-
1
-
-
0032585233
-
Trials: The next 50 years. Large scale randomised evidence of moderate benefits
-
Editorial,PMID: 9794846
-
Peto R, Baigent C. Trials: The next 50 years. Large scale randomised evidence of moderate benefits [Editorial]. BMJ. 1998;317: 1170-1. [PMID: 9794846].
-
(1998)
BMJ
, vol.317
, pp. 1170-1171
-
-
Peto, R.1
Baigent, C.2
-
3
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
PMID: 2702835
-
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. [PMID: 2702835].
-
(1989)
Control Clin Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
4
-
-
84939864059
-
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
-
PMID: 26287849
-
Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726-36. [PMID: 26287849] doi:10.1056/NEJMoa1502309.
-
(2015)
N Engl J Med.
, vol.373
, pp. 726-736
-
-
Hyman, D.M.1
Puzanov, I.2
Subbiah, V.3
Faris, J.E.4
Chau, I.5
Blay, J.Y.6
-
5
-
-
84904211802
-
Molecular analysis for therapy choice: NCI MATCH [Editorial]
-
PMID: 25023344
-
Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH [Editorial]. Semin Oncol. 2014;41:297-9. [PMID: 25023344] doi:10.1053/j.seminoncol.2014.05.002.
-
(2014)
Semin Oncol.
, vol.41
, pp. 297-299
-
-
Conley, B.A.1
Doroshow, J.H.2
-
6
-
-
84978682921
-
Group mentality: Determining if targeted treatments really work for cancer
-
PMID: 26937611
-
Chakradhar S. Group mentality: determining if targeted treatments really work for cancer. Nat Med. 2016;22:222-4. [PMID: 26937611] doi:10.1038/nm0316-222.
-
(2016)
Nat Med.
, vol.22
, pp. 222-224
-
-
Chakradhar, S.1
-
7
-
-
67650345287
-
Multiple histology phase II trials
-
PMID: 19549777
-
Leblanc M, Rankin C, Crowley J. Multiple histology phase II trials. Clin Cancer Res. 2009;15:4256-62. [PMID: 19549777] doi:10.1158/1078-0432.CCR-08-2069.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 4256-4262
-
-
Leblanc, M.1
Rankin, C.2
Crowley, J.3
-
8
-
-
0037445360
-
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes
-
PMID: 12587104
-
Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med. 2003;22:763-80. [PMID: 12587104].
-
(2003)
Stat Med.
, vol.22
, pp. 763-780
-
-
Thall, P.F.1
Wathen, J.K.2
Bekele, B.N.3
Champlin, R.E.4
Baker, L.H.5
Benjamin, R.S.6
-
9
-
-
84875133582
-
Borrowing information across subgroups in phase II trials: Is it useful?
-
PMID: 23303215
-
Freidlin B, Korn EL. Borrowing information across subgroups in phase II trials: is it useful? Clin Cancer Res. 2013;19:1326-34. [PMID: 23303215] doi:10.1158/1078-0432.CCR-12-1223.
-
(2013)
Clin Cancer Res.
, vol.19
, pp. 1326-1334
-
-
Freidlin, B.1
Korn, E.L.2
-
10
-
-
84960348344
-
The Bayesian basket design for genomic variant-driven phase II trials
-
PMID: 26970120
-
Simon R, Geyer S, Subramanian J, Roychowdhury S. The Bayesian basket design for genomic variant-driven phase II trials. Semin Oncol. 2016;43:13-8. [PMID: 26970120] doi:10.1053/j.seminoncol.2016.01.002.
-
(2016)
Semin Oncol.
, vol.43
, pp. 13-18
-
-
Simon, R.1
Geyer, S.2
Subramanian, J.3
Roychowdhury, S.4
-
11
-
-
84925377660
-
Application of molecular profiling in clinical trials for advanced metastatic cancers
-
PMID: 25663694
-
Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, et al. Application of molecular profiling in clinical trials for advanced metastatic cancers. J Natl Cancer Inst. 2015;107. [PMID: 25663694] doi:10.1093/jnci/djv003.
-
(2015)
J Natl Cancer Inst.
, vol.107
-
-
Kummar, S.1
Williams, P.M.2
Lih, C.J.3
Polley, E.C.4
Chen, A.P.5
Rubinstein, L.V.6
-
12
-
-
84954026435
-
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-ofconcept, randomised, controlled phase 2 trial
-
SHIVA investigators, [PMID: 26342236]
-
Le Tourneau, C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al; SHIVA investigators. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-ofconcept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16:1324-34. [PMID: 26342236] doi:10.1016/S1470-2045(15)00188-6.
-
(2015)
Lancet Oncol.
, vol.16
, pp. 1324-1334
-
-
Delord, J.P.1
Gonçalves, A.2
Gavoille, C.3
Dubot, C.4
Isambert, N.5
Le Tourneau, C.6
-
13
-
-
84880206315
-
Clinical trials for precision oncology using next generation sequencing
-
Simon R, Polley E. Clinical trials for precision oncology using next generation sequencing. Per Med. 2013;10:485-95.
-
(2013)
Per Med.
, vol.10
, pp. 485-495
-
-
Simon, R.1
Polley, E.2
-
14
-
-
79957857433
-
The BATTLE trial: Personalizing therapy for lung cancer
-
PMID: 22586319
-
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1:44-53. [PMID: 22586319] doi:10.1158/2159-8274.CD-10-0010.
-
(2011)
Cancer Discov.
, vol.1
, pp. 44-53
-
-
Kim, E.S.1
Herbst, R.S.2
Wistuba, I.I.3
Lee, J.J.4
Blumenschein, G.R.5
Tsao, A.6
-
15
-
-
78650339993
-
Outcome- Adaptive randomization: Is it useful?
-
PMID: 21172882
-
Korn EL, Freidlin B. Outcome- Adaptive randomization: is it useful? J Clin Oncol. 2011;29:771-6. [PMID: 21172882] doi:10.1200/JCO.2010.31.1423.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 771-776
-
-
Korn, E.L.1
Freidlin, B.2
-
16
-
-
0032844121
-
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
-
Herceptin Multinational Investigator Study Group., [PMID: 10482196
-
Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 1999;26:71-7. [PMID: 10482196].
-
(1999)
Semin Oncol.
, vol.26
, pp. 71-77
-
-
Shak, S.1
-
17
-
-
84868481873
-
Vemurafenib: The first drug approved for BRAF-mutant cancer
-
PMID: 23060265
-
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11:873-86. [PMID: 23060265] doi:10.1038/nrd3847.
-
(2012)
Nat Rev Drug Discov.
, vol.11
, pp. 873-886
-
-
Bollag, G.1
Tsai, J.2
Zhang, J.3
Zhang, C.4
Ibrahim, P.5
Nolop, K.6
-
18
-
-
84939575246
-
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: A paradigm for precision cancer medicine
-
PMID: 25979929
-
Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: A paradigm for precision cancer medicine. Clin Cancer Res. 2015;21:2227-35. [PMID: 25979929] doi:10.1158/1078-0432.CCR-14-2791.
-
(2015)
Clin Cancer Res.
, vol.21
, pp. 2227-2235
-
-
Katayama, R.1
Lovly, C.M.2
Shaw, A.T.3
-
19
-
-
0020974571
-
Sample-size formula for the proportionalhazards regression model
-
PMID: 6354290
-
Schoenfeld DA. Sample-size formula for the proportionalhazards regression model. Biometrics. 1983;39:499-503. [PMID: 6354290].
-
(1983)
Biometrics
, vol.39
, pp. 499-503
-
-
Schoenfeld, D.A.1
-
20
-
-
6044278144
-
Evaluating the efficiency of targeted designs for randomized clinical trials
-
PMID: 15501951
-
Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res. 2004;10: 6759-63. [PMID: 15501951].
-
(2004)
Clin Cancer Res.
, vol.10
, pp. 6759-6763
-
-
Simon, R.1
Maitournam, A.2
-
21
-
-
84927606243
-
Lung Master Protocol (Lung-MAP)- A biomarkerdriven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400
-
PMID: 25680375
-
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung Master Protocol (Lung-MAP)- A biomarkerdriven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21: 1514-24. [PMID: 25680375] doi:10.1158/1078-0432.CCR-13-3473.
-
(2015)
Clin Cancer Res.
, vol.21
, pp. 1514-1524
-
-
Herbst, R.S.1
Gandara, D.R.2
Hirsch, F.R.3
Redman, M.W.4
LeBlanc, M.5
Mack, P.C.6
-
22
-
-
85018221048
-
Improving clinical trial efficiency: Thinking outside the box
-
PMID: 25993165
-
Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: Thinking outside the box. Am Soc Clin Oncol Educ Book. 2015:141-7. [PMID: 25993165] doi:10.14694/EdBook-AM.2015.35.e141.
-
(2015)
Am Soc Clin Oncol Educ Book
, pp. 141-147
-
-
Mandrekar, S.J.1
Dahlberg, S.E.2
Simon, R.3
-
23
-
-
84932126124
-
ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer
-
PMID: 25677079
-
Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther. 2015;97:447-50. [PMID: 25677079] doi:10.1002/cpt.91.
-
(2015)
Clin Pharmacol Ther.
, vol.97
, pp. 447-450
-
-
Gerber, D.E.1
Oxnard, G.R.2
Govindan, R.3
-
24
-
-
85018231159
-
Changing the paradigm-multistage multiarm randomized trials and stratified cancer medicine [Editorial]
-
S-CORT Consortium., [PMID: 26070918
-
Lawler M, Kaplan R, Wilson RH, Maughan T; S-CORT Consortium. Changing the paradigm-multistage multiarm randomized trials and stratified cancer medicine [Editorial]. Oncologist. 2015;20: 849-51. [PMID: 26070918] doi:10.1634/theoncologist.2015-0014.
-
(2015)
Oncologist
, vol.20
, pp. 849-851
-
-
Lawler, M.1
Kaplan, R.2
Wilson, R.H.3
Maughan, T.4
-
25
-
-
84877278637
-
Implementing personalized cancer genomics in clinical trials
-
PMID: 23629504
-
Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013;12:358-69. [PMID: 23629504] doi:10.1038/nrd3979.
-
(2013)
Nat Rev Drug Discov.
, vol.12
, pp. 358-369
-
-
Simon, R.1
Roychowdhury, S.2
-
26
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
BRIM-3 Study Group., [PMID: 21639808]
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16. [PMID: 21639808] doi:10.1056/NEJMoa1103782.
-
(2011)
N Engl J Med.
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
-
27
-
-
84918804764
-
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
-
PROFILE 1014 Investigators., [PMID: 25470694
-
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167- 77. [PMID: 25470694] doi:10.1056/NEJMoa1408440.
-
(2014)
N Engl J Med.
, vol.371
, pp. 2167-2177
-
-
Solomon, B.J.1
Mok, T.2
Kim, D.W.3
Wu, Y.L.4
Nakagawa, K.5
Mekhail, T.6
|